Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus

Astellas

Status and phase: Completed; Phase 2

Conditions: Type 1 Diabetes Mellitus

Treatments: Drug: ASP1941; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT02529449

1941-CL-6001

Details and patient eligibility

About

The objective of this study is to assess pharmacodynamics, pharmacokinetics, and safety of ASP1941 in patients with type 1 diabetes mellitus when administered once daily (q.d.) for 2 weeks.

Enrollment: 43 patients

Sex: All

Ages: 20 to 74 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

At the time of obtaining informed consent:

• Subject is diagnosed with type 1 diabetes mellitus and has been treated with insulin therapy for at least 52 weeks (364 days).
• Subject is able to be admitted to the site as scheduled.
• Subject is able to record in Patient's diary from the first study drug dose in observation period until the day before the end of post observation.

At screening period:

• Subject has an HbA1c (NGSP) value of between 7.5% and 10.0%. If subject has an HbA1c value of between 7.3% and 10.2% (out of the reference range), HbA1c may be re-measured only once within the allowance range in screening period. Re-measured HbA1c (NGSP) value will be adopted for the determination.
• Subject has been receiving insulin therapy at daily doses (instructed by a doctor) within a ±20% range for at least 12weeks (83days) prior to the start of screening.
• Subject has a fasting serum C-peptide level ≤0.5 ng/mL at screening.
• Subject receives treatments for complications (except for transient diseases such as a cold) that, in the investigator's or sub-investigator's opinion, need not to be changed during the period from the start of screening to the end of the treatment period.
• Subject has body mass index (BMI) value of 20.0 to 35.0 kg/m2 at screening.

Exclusion criteria

At the time of obtaining informed consent:

• Subject has type 2 diabetes mellitus.
• Subject has participated or has been participating in a clinical study or a post marketing study of another drug or medical equipment within 12 weeks (84 days) prior to obtaining informed consent.
• Subject has received ASP1941 (ipragliflozin) with the exception of placebo.

At screening period:

• Subject has proliferative retinopathy (subjects with stable condition after photocoagulation etc. may be enrolled in the study).
• Subject has developed hypoglycemia unawareness (requires help of a third person) or severe hypoglycemia (diabetic coma, precoma, or convulsion) within 12 weeks (84 days) prior to the start of screening.
• Subject has developed diabetic ketoacidosis within 12 weeks (84 days) prior to the start of screening.
• Subject has chronic disease(s) which require the continuous use of corticosteroids or immunosuppressants (oral administration, injection, inhalation, or suppository).
• Subject has received hypoglycemic agent(s) other than insulin within 12 weeks (83 days) prior to the start of screening.
• Subject with perioperative, severe infection or serious injury.
• Subject whose serum creatinine value exceeds the upper limit of normal range at screening.
• Subject has a urinary albumin/urinary creatinine ratio>300 mg/g in urinalysis at screening.
• Subject has a history of clinically significant renal disease(s) such as renovascular occlusive disease, nephrectomy, and/or renal transplant.
• Subject has AST and ALT >2 ×ULN or T-Bil >1.5 × ULN at screening, or has a history of serious hepatic diseases.
• Subject presents with symptoms of dysuria, anuria, oliguria and urinary retention.
• Subject has a history of recurrent urinary tract infections and recurrent genital infections (developed 3 times or more within 24 weeks (168 days) prior to the start of screening).
• Subject has urinary tract infection or genital infection with subjective symptoms.
• Subject has a history of angina unstable, myocardial infarction, angioplasty, and serious heart disease (NYHA Class II-IV) within 24 weeks (168 days) prior to the start of screening, or has complications of heart disease that, in the investigator's or sub-investigator's opinion, may interfere with the evaluation of safety of ASP1941.
• Subject has uncontrolled blood pressure (systolic blood pressure≥160 mmHg or diastolic blood pressure≥100 mmHg in the supine position after a 5-minute rest at screening ).
• Subject has serious gastrointestinal disease or a history of serious gastrointestinal operation.
• Subject has malignant tumors concomitantly (subject may be enrolled in the study if the subject has a history of a malignant tumor which has not recurred without any treatment within 5 years prior to the start of screening).
• Subject has psychiatric disorder that makes the subject unsuitable for study participation.
• Subject has drug addiction or alcohol abuse.
• Subject has a history of drug allergies.
• Subject is unable to adhere to any of the compliance such as hospital visits and dose instruction specified in this study, or does not agree with it.
• Subject has donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days prior to the start of screening.
• Subject has any condition that, in the investigator's or sub-investigator's opinion, makes the subject unsuitable for study participation.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

43 participants in 4 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

once daily

Treatment:

Drug: Placebo

ASP1941 Low dose group

Experimental group

Description:

once daily

Treatment:

Drug: ASP1941

ASP1941 Middle dose group

Experimental group

Description:

once daily

Treatment:

Drug: ASP1941

ASP1941 High dose group

Experimental group

Description:

once daily

Treatment:

Drug: ASP1941